

## Special Issue

# Signaling Networks and Gene Expression in Immune Cells

### Message from the Guest Editors

Innate and adaptive immune responses are shaped by intricate signaling networks. During immune cell activation, metabolism becomes highly adaptable to promptly provide necessary materials according to the organism's requirements. Metabolic processes provide nutrients and energy and also contribute to gene expression reprogramming and transcription of multiple signal proteins. The metabolic and transcriptional profiles drive the development of various immune cell subsets. Indeed, metabolic signaling is closely related to epigenetic and, in turn, gene expression changes in both innate and adaptive immune cells. For our upcoming Special Issue, we invite researchers to contribute their valuable work, whether original research or review articles, on the most recent findings of signaling networks, including immunometabolic pathways and mechanisms of gene expression in immune cells. We further encourage contributions that delve into the regulation, mechanisms, pathways, gene expression reprogramming, cell types, and mediators involved in the interplay between immunity and metabolism, as well as emerging therapies.

---

### Guest Editors

Dr. Santarsiero Anna

Dr. Vittoria Infantino

Dr. Paolo Convertini

---

### Deadline for manuscript submissions

31 March 2025



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/185419](https://mdpi.com/si/185419)

*Biomedicines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).